MA
RXST icon

MCF Advisors’s RxSight RXST Stock Holding History

MCF Advisors’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-187
Closed -$4.72K – 933
2025
Q1 		$4.72K Hold
187
– – ﹤0.01% 748
2024
Q4 		$6.43K Sell
187
-470
-72% -$21.2K ﹤0.01% 730
2024
Q3 		$32.5K Buy
657
+54
+9% +$2.77K ﹤0.01% 459
2024
Q2 		$36.3K Hold
603
– – ﹤0.01% 443
2024
Q1 		$31.1K Sell
603
-182
-23% -$8.93K ﹤0.01% 458
2023
Q4 		$31.7K Sell
785
-121
-13% -$3.55K ﹤0.01% 439
2023
Q3 		$25.3K Sell
906
-107
-11% -$3.19K ﹤0.01% 451
2023
Q2 		$29.2K Sell
1,013
-50
-5% -$1.11K ﹤0.01% 430
2023
Q1 		$17.7K Buy
1,063
+279
+36% +$3.94K ﹤0.01% 488
2022
Q4 		$9.93K Buy
+784
New +$9.54K ﹤0.01% 534

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
NSGL
No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MCF Advisors's RXST Position: Q2 2025 in Review

MCF Advisors sold out of RxSight (RXST) in Q2 2025, closing a stake of 187 shares — an estimated $4.72K sold.

MCF Advisors first reported a position in RXST in Q4 2022 and held it in 10 quarters. The position peaked at $36.3K in Q2 2024. 174 funds tracked by Wall St. Rank hold RXST as of Q2 2025.

  • MCF Advisors reported no remaining RxSight position as of Q2 2025 after selling out during the quarter.
  • MCF Advisors sold 187 RxSight shares in Q2 2025, an estimated $4.72K.
  • MCF Advisors first reported a position in RxSight in Q4 2022 and held it in 10 quarters.
  • MCF Advisors's RxSight position peaked at $36.3K in Q2 2024.
  • 174 funds tracked by Wall St. Rank held RxSight as of Q2 2025.

Based on MCF Advisors's 13F filing for Q2 2025, filed 15 Jul 2025.